Lymphoma, T-Cell: all 723 studies

Page 4 of 8. Open to participants first (121), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).Active, not recruitingNCT06550336Phase 2
• A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLActive, not recruitingNCT06547528Phase 1
• Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell LymphomaActive, not recruitingNCT06492629Phase 2
• A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesCompletedNCT06492304Phase 1/2
• Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line TherapyCompletedNCT06422247
• ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell LymphomaCompletedNCT06149390
• A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingNCT06035497Phase 1/2
• Study of Tazemetostat in Lymphoid MalignanciesTerminatedNCT05983965Phase 1
• A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab VedotinCompletedNCT05886478
• Skin Barrier and Microbiome of CTCL PatientsCompletedNCT05827107
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.Status unknownNCT05821192Not applicable
• Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell LymphomaStatus unknownNCT05774028Phase 2
• Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)Status unknownNCT05772728Not applicable
• A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
• A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell LymphomaStatus unknownNCT05569057Phase 1
• Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLLStatus unknownNCT05557903Phase 1
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell TransplantActive, not recruitingNCT05540340Phase 1
• A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell LymphomaStatus unknownNCT05527275Phase 1/2
• A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell LymphomaStatus unknownNCT05495100Phase 2
• Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell LymphomaActive, not recruitingNCT05464433Phase 1/2
• SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid MalignanciesStatus unknownNCT05398614Phase 1
• Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell LymphomaStatus unknownNCT05387226Phase 1
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 1
• Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2CompletedNCT05321147Phase 1
• Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell LymphomaStatus unknownNCT05316246Phase 2
• Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell MalignanciesCompletedNCT05290155Phase 1
• MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
• Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCLWithdrawnNCT05239910Phase 2
• Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsCompletedNCT05225584Phase 1
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaStatus unknownNCT05208853Early Phase 1
• Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
• A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).TerminatedNCT05156229Phase 1
• Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownNCT05149170Phase 2
• A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCLSuspendedNCT05138458Phase 1/2
• A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)CompletedNCT05137847
• An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)No longer availableNCT05131438
• Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell MalignanciesStatus unknownNCT05127135Phase 1
• Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell LymphomasTerminatedNCT05105412Phase 1/2
• Study of ONO-4685 in Patients With Relapsed or Refractory T Cell LymphomaActive, not recruitingNCT05079282Phase 1
• CD7 CAR T-cell for R/R CD7+ T Cell LymphomaStatus unknownNCT05059912Phase 2
• Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
• CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's LymphomaStatus unknownNCT05013372Early Phase 1
• Brentuximab Vedotin in Combination With CHEP in Patient With PTCLStatus unknownNCT05006664Phase 2
• A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotinCompletedNCT04998331
• Study of Lacutamab in Peripheral T-cell LymphomaActive, not recruitingNCT04984837Phase 2
• Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell MalignancesStatus unknownNCT04934774Phase 1
• Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ LymphomaStatus unknownNCT04928105Not applicable
• GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaStatus unknownNCT04917250Phase 2
• Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell LymphomaStatus unknownNCT04899414Phase 2
• Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
• Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesSuspendedNCT04828174Phase 1
• Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies MalignanciesStatus unknownNCT04823091Phase 1
• Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
• Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedNCT04774068Phase 1
• Mogamulizumab Q4week Dosing in Participants With R/R CTCLActive, not recruitingNCT04745234Phase 2
• Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaActive, not recruitingNCT04712864Phase 1
• Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT04702503Phase 1
• Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsStatus unknownNCT04696705Early Phase 1
• Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTLStatus unknownNCT04676789Phase 2
• Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis FungoidesTerminatedNCT04676087Phase 1/2
• CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.Status unknownNCT04653649Phase 1/2
• A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）Status unknownNCT04615468Phase 2
• Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) TrialTerminatedNCT04602065Phase 1/2
• Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell MalignanciesStatus unknownNCT04594135Phase 1
• Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaActive, not recruitingNCT04526834Phase 1
• Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell LymphomaStatus unknownNCT04511351Not applicable
• Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell LymphomaCompletedNCT04509804
• A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)TerminatedNCT04502446Phase 1
• Diagnostic Classifier for Cutaneous T-cell LymphomasStatus unknownNCT04491825
• A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell LymphomaStatus unknownNCT04490590Phase 4
• CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 1
• Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional ChemotherapyStatus unknownNCT04480125Phase 2
• Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaActive, not recruitingNCT04480099Phase 2
• A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell LymphomaStatus unknownNCT04470141Phase 2
• The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Status unknownNCT04457830Phase 2
• A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT04444141Phase 1/2
• Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell LymphomaStatus unknownNCT04423536
• GPED Regimen for Relapsed/Refractory or Advanced ENKTCLStatus unknownNCT04405375Phase 2
• Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell LymphomaStatus unknownNCT04338282Phase 2
• Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCLStatus unknownNCT04337593Phase 2
• Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell LymphomasWithdrawnNCT04334174Phase 2
• Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell LymphomasTerminatedNCT04331119Phase 2
• Rituximab Combined With Chidamide and Lenalidomide for r/r AITLStatus unknownNCT04319601Not applicable
• Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II StudyStatus unknownNCT04296786Phase 2
• Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell LymphomaWithdrawnNCT04233697Phase 1
• Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell LymphomaWithdrawnNCT04230330Phase 1
• Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
• LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell LymphomaTerminatedNCT04219319Phase 1
• REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)TerminatedNCT04218825Phase 2
• A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)CompletedNCT04171791Phase 1
• CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell MalignanciesStatus unknownNCT04162340Phase 1
• CAR-37 T Cells in Hematologic MalignanciesCompletedNCT04136275Phase 1
• ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose ChemotherapyCompletedNCT04121507Phase 2
• Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.Status unknownNCT04118868Phase 1
• A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus unknownNCT04108325Phase 1
• Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell LymphomaStatus unknownNCT04096690Phase 2
• A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesActive, not recruitingNCT04072458Phase 1
• A Study of Bortezomib Combined With CHEP in Peripheral T Cell LymphomaStatus unknownNCT04061772Phase 2
• PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell LymphomaStatus unknownNCT04040491Phase 4

← Lymphoma, T-Cell overview